Additionaly, in the absence of NCTD treatment, GSK126 treatment did not significantly upregulated TOP2A expression, suggesting that there are no H3K27me3 binding peaks in TOP2A gene in HCC. This evidence concerns the gene TOP2A and hepatocellular carcinoma.